Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
暂无分享,去创建一个
[1] R. Louis,et al. Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma , 2021, European Respiratory Journal.
[2] D. Barber,et al. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice , 2021, The Journal of experimental medicine.
[3] H. Simon,et al. The Enigma of Eosinophil Degranulation , 2021, International journal of molecular sciences.
[4] I. Pavord,et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma , 2021, European Respiratory Journal.
[5] N. Hacohen,et al. Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell production from hematopoietic progenitors in vitro , 2021, Science Translational Medicine.
[6] M. Idzko,et al. Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes , 2021, Journal of asthma and allergy.
[7] S. Berdnikovs. The twilight zone: plasticity and mixed ontogeny of neutrophil and eosinophil granulocyte subsets , 2021, Seminars in Immunopathology.
[8] I. Pavord,et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. , 2021, The Lancet. Respiratory medicine.
[9] Y. Politanska,et al. More than neutrophils: Lin(+)Ly6G(+)IL‐5Rα(+) multipotent myeloid cells (MMCs) are dominant in normal murine bone marrow and retain capacity to differentiate into eosinophils and monocytes , 2021, Journal of leukocyte biology.
[10] J. L. Dunn,et al. Bidirectional Crosstalk Between Eosinophils and Esophageal Epithelial Cells Regulates Inflammatory and Remodeling Processes , 2021, Mucosal Immunology.
[11] H. Hammad,et al. The basic immunology of asthma , 2021, Cell.
[12] A. Nanzer,et al. Real world effectiveness of anti-IL5/5R therapy in severe atopic eosinophilic asthma with fungal sensitisation. , 2021, The journal of allergy and clinical immunology. In practice.
[13] I. Pavord,et al. Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. , 2021, Annual review of immunology.
[14] H. Dweep,et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice , 2021, The Journal of experimental medicine.
[15] M. Guilliams,et al. Does tissue imprinting restrict macrophage plasticity? , 2021, Nature Immunology.
[16] S. Ackerman,et al. A tribute to eosinophils from a comparative and evolutionary perspective. , 2021, The Journal of allergy and clinical immunology.
[17] G. Canonica,et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. , 2020, The Lancet. Respiratory medicine.
[18] I. Pavord,et al. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On The Path to Personalized Medicine. , 2020, The journal of allergy and clinical immunology. In practice.
[19] P. Nair,et al. Asthma exacerbations on benralizumab are largely non‐eosinophilic , 2020, Allergy.
[20] L. Boulet,et al. The Management of Severe Asthma in 2020. , 2020, Biochemical pharmacology.
[21] Yin-fang Wu,et al. Homeostatic and early-recruited CD101− eosinophils suppress endotoxin-induced acute lung injury , 2020, European Respiratory Journal.
[22] J. Mikes,et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 , 2020, Cell Reports Medicine.
[23] R. Louis,et al. Advances toward precision medicine for asthma. , 2020, Biochemical pharmacology.
[24] E. V. van Roon,et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. , 2020, Biochemical pharmacology.
[25] R. Louis,et al. Eosinophil diversity in asthma. , 2020, Biochemical pharmacology.
[26] K. McCoy,et al. The emerging roles of eosinophils in mucosal homeostasis , 2020, Mucosal Immunology.
[27] M. Humbert,et al. Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma. , 2020, The journal of allergy and clinical immunology. In practice.
[28] S. Ackerman,et al. Contributions of Eosinophils to Human Health and Disease. , 2020, Annual review of pathology.
[29] A. Fryer,et al. IL-5 Exposure in utero Increases Lung Nerve Density and Causes Airway Reactivity in Adult Offspring. , 2019, American journal of respiratory cell and molecular biology.
[30] I. Pavord,et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis. , 2019, American journal of respiratory and critical care medicine.
[31] F. Albers,et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. , 2019, Respiratory medicine.
[32] F. Albers,et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA , 2019, Respiratory Research.
[33] G. Chupp,et al. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. , 2019, The Journal of allergy and clinical immunology.
[34] F. Albers,et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. , 2019, Respiratory medicine.
[35] H. Hammad,et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment , 2019, Science.
[36] Supat Thongjuea,et al. Identification of two distinct pathways of human myelopoiesis , 2019, Science Immunology.
[37] H. Ortega,et al. Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.
[38] C. Nerlov,et al. Haematopoiesis in the era of advanced single-cell technologies , 2019, Nature Cell Biology.
[39] Allon M. Klein,et al. Lineage tracing on transcriptional landscapes links state to fate during differentiation , 2018, Science.
[40] V. Witko-Sarsat,et al. Expanding Neutrophil Horizons: New Concepts in Inflammation , 2018, Journal of Innate Immunity.
[41] A. Fryer,et al. Eosinophils increase airway sensory nerve density in mice and in human asthma , 2018, Science Translational Medicine.
[42] E. Bleecker,et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma , 2018, European Respiratory Journal.
[43] A. Fryer,et al. Eosinophil and airway nerve interactions in asthma , 2018, Journal of leukocyte biology.
[44] James J. Lee,et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease , 2018, Journal of leukocyte biology.
[45] J. Lasky,et al. A critical role for IL-18 in transformation and maturation of naive eosinophils to pathogenic eosinophils. , 2018, The Journal of allergy and clinical immunology.
[46] Jessica E. Bolden,et al. Transcriptional profiling of eosinophil subsets in interleukin‐5 transgenic mice , 2018, Journal of leukocyte biology.
[47] B. Chipps,et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[48] F. Roufosse. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma , 2018, Front. Med..
[49] Samuel L. Wolock,et al. Population Snapshots Predict Early Hematopoietic and Erythroid Hierarchies , 2018, Nature.
[50] Lin Ying Liu,et al. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma , 2017, American journal of respiratory and critical care medicine.
[51] B. Lambrecht,et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects , 2017, mAbs.
[52] T. Marichal,et al. Homeostatic Eosinophils: Characteristics and Functions , 2017, Front. Med..
[53] W. Busse,et al. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment , 2017, The Journal of Allergy and Clinical Immunology: In Practice.
[54] G. Brusselle,et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. , 2017, Pulmonary pharmacology & therapeutics.
[55] W. Busse,et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.
[56] E. Bleecker,et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.
[57] J. Corren,et al. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.
[58] C. Lemière,et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.
[59] M. Thiry,et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. , 2016, The Journal of clinical investigation.
[60] Christopher E Brightling,et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.
[61] R. Sakalauskas,et al. Eosinophils enhance WNT-5a and TGF-β1 genes expression in airway smooth muscle cells and promote their proliferation by increased extracellular matrix proteins production in asthma , 2016, BMC Pulmonary Medicine.
[62] Alice Giustacchini,et al. Distinct myeloid progenitor differentiation pathways identified through single cell RNA sequencing , 2016, Nature Immunology.
[63] A. Misharin,et al. Phenotypic plasticity and targeting of Siglec‐FhighCD11clow eosinophils to the airway in a murine model of asthma , 2016, Allergy.
[64] N. Paul,et al. Circulating Human Eosinophils Share a Similar Transcriptional Profile in Asthma and Other Hypereosinophilic Disorders , 2015, PloS one.
[65] Helen K. Reddel,et al. A summary of the new GINA strategy: a roadmap to asthma control , 2015, European Respiratory Journal.
[66] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[67] H. Hammad,et al. The immunology of asthma , 2014, Nature Immunology.
[68] Paige Lacy,et al. Eosinophil Cytokines, Chemokines, and Growth Factors: Emerging Roles in Immunity , 2014, Front. Immunol..
[69] M. Rothenberg,et al. IL-5 Triggers a Cooperative Cytokine Network That Promotes Eosinophil Precursor Maturation , 2014, The Journal of Immunology.
[70] R. Louis,et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma , 2014, European Respiratory Journal.
[71] E. Bleecker,et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.
[72] W. Busse,et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.
[73] R. Flavell,et al. TH2, allergy and group 2 innate lymphoid cells , 2013, Nature Immunology.
[74] M. Henket,et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation , 2013, BMC Pulmonary Medicine.
[75] James J. Lee,et al. Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red". , 2012, The Journal of allergy and clinical immunology.
[76] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[77] M. Bivas-Benita,et al. CCL11 elicits secretion of RNases from mouse eosinophils and their cell‐free granules , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[78] W. Crawford,et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. , 2011, The Journal of allergy and clinical immunology.
[79] J. Connolly,et al. Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus , 2011, Science Translational Medicine.
[80] James J. Lee,et al. Eosinophils in health and disease: the LIAR hypothesis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[81] Barmak Modrek,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.
[82] K. Akashi,et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor , 2009, The Journal of experimental medicine.
[83] A. Dvorak,et al. Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule‐derived cytokines and other proteins , 2008, Journal of leukocyte biology.
[84] D. Robinson,et al. The role of eosinophils in airway tissue remodelling in asthma. , 2007, Current opinion in immunology.
[85] W. Busse,et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.
[86] R. Scott,et al. Inflammatory subtypes in asthma: Assessment and identification using induced sputum , 2006, Respirology.
[87] S. Peters,et al. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. , 2005, The Journal of allergy and clinical immunology.
[88] K. Akashi,et al. Identification of eosinophil lineage–committed progenitors in the murine bone marrow , 2005, The Journal of experimental medicine.
[89] E. Israel,et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. , 2005, The Journal of allergy and clinical immunology.
[90] J. Denburg,et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. , 2003, The Journal of allergy and clinical immunology.
[91] A. Kay,et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.
[92] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.
[93] C. Jenkins,et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. , 2001, American journal of respiratory and critical care medicine.
[94] K. Chung,et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.
[95] S. Wenzel,et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.
[96] P. Howarth,et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. , 1997, American journal of respiratory and critical care medicine.
[97] E. Gelfand,et al. Interleukin-5 Expression in the Lung Epithelium of Transgenic Mice Leads to Pulmonary Changes Pathognomonic of Asthma , 1997, The Journal of experimental medicine.
[98] L. Lichtenstein,et al. Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. , 1994, The Journal of allergy and clinical immunology.
[99] D. Wong,et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. , 1991, Blood.
[100] T. Fukuda,et al. Heterogeneity of human eosinophils. , 1989, The Journal of allergy and clinical immunology.
[101] M. Peters,et al. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. , 1988, Blood.
[102] M. Peters,et al. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. , 1985, The American review of respiratory disease.
[103] A. Capron,et al. Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density. , 1984, Clinical and experimental immunology.
[104] B. Chipps,et al. Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[105] E. Bleecker,et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.
[106] M. Rothenberg,et al. Eosinophil Development, Disease Involvement, and Therapeutic Suppression. , 2018, Advances in immunology.
[107] K. Chung,et al. Precision medicine in asthma: linking phenotypes to targeted treatments , 2018, Current opinion in pulmonary medicine.
[108] L. Swedin,et al. Patient stratification and the unmet need in asthma. , 2017, Pharmacology & therapeutics.
[109] Shiori Yamamoto,et al. Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. , 2016, The Journal of allergy and clinical immunology.
[110] S. Willsie. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .
[111] P. Hodgkin,et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. , 1996, Immunity.